FDA lifts clinical hold on Translate Bio's targeted mRNA candidate

13 April 2018

Massachusetts, USA-based messenger RNA (mRNA) specialist Translate Bio says the US Food and Drug Administration has cleared the company to begin a first-in-human clinical trial of MRT5005 in patients with cystic fibrosis.

MRT5005 is an mRNA therapeutic candidate that is designed to treat patients with cystic fibrosis by addressing the underlying cause of the disease.

The FDA had reportedly requested more detailed information for the drug related to chemistry, manufacturing and controls (CMC), delaying the green light for a few months. The company now says it intends to start dosing patients in a Phase I/II clinical trial in mid-2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK